Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...

Biopharmaceutics and Pharmacokinetics: Overview

Biopharmaceutics and Pharmacokinetics: Overview

Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Review of Quality Attributes and Analytical Methods Used for Comparative Analytical Assessment of Monoclonal Antibodies as Part of Successful Biosimilar Approvals in the United States and European Union.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026

Same author

Response to comment on "A quantitative metric of immune responses with applications in vaccines, cancer immunity, autoimmunity, and anti-drug antibody monitoring".

Journal of pharmaceutical sciences·2026

Same author

A quantitative metric of immune responses with applications in vaccines, cancer immunity, autoimmunity, and anti-drug antibody monitoring.

Journal of pharmaceutical sciences·2026

Same author

Cytokine expression mediated immunogenic response of therapeutic IgG aggregates obtained by forced degradative stress factors and the role of a deep neural network in its prediction.

Biochemical and biophysical research communications·2026

Same author

Correction to: Brain dystrophinopathies and cognitive impairment: Pathogenesis, diagnosis, and therapies.

Journal of biosciences·2026

Same author

Brain dystrophinopathies and cognitive impairment: Pathogenesis, diagnosis, and therapies.

Journal of biosciences·2025

Search research articles

Related Experiment Video

Updated: Oct 11, 2025

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

Biopharmaceutical Industry Capability Building in India: Report from a Symposium.

Annu Uppal¹, Ranjan Chakrabarti¹, Narendra Chirmule²

¹US Pharmacopeia India Pvt Ltd, Hyderabad, Telangana India.

Journal of Pharmaceutical Innovation

|December 1, 2021

Summary

The biopharmaceutical industry is shifting to cell and gene therapies. Experts recommend focusing on skilled workforces, advanced manufacturing, and favorable policies to meet global standards and improve drug delivery in developing nations.

Keywords:

Biopharmaceutical Capability Manufacturing Quality Regulatory

More Related Videos

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

Related Experiment Videos

Last Updated: Oct 11, 2025

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Process Optimization using High Throughput Automated Micro-Bioreactors in Chinese Hamster Ovary Cell Cultivation

Published on: May 18, 2020

Area of Science:

Biopharmaceutical Manufacturing
Biotechnology Sector Development

Background:

The biopharmaceutical industry is transitioning from traditional biologics to complex cell and gene therapies.
Global competitiveness requires adherence to quality standards, reduced manufacturing failures, and accelerated drug delivery.
Developing nations face challenges in meeting these evolving industry demands.

Purpose of the Study:

To discuss the requirements and identify gaps in biotechnology and pharmaceutical sectors in India and other developing countries.
To outline key drivers for capability building in the biopharmaceutical industry.
To summarize expert recommendations for enhancing biomanufacturing in emerging economies.

Main Methods:

A symposium was convened by the US Pharmacopeia (USP), Department of Biotechnology (DBT) India, and Confederation of Indian Industry (CII).
A panel of experts from academia, manufacturing, and government agencies was assembled.
Discussions focused on industry needs, challenges, and strategic recommendations.

Main Results:

Key drivers for capability building were identified, including a skilled workforce, public-private partnerships, and advanced manufacturing technologies.
The need for novel biologics development and supportive policy frameworks was highlighted.
Specific recommendations were formulated to address identified gaps in the sector.

Conclusions:

Enhancing biomanufacturing capabilities in developing countries requires a strategic, multifaceted approach.
Investment in workforce development, technology, and policy is crucial for global competitiveness.
Collaborative efforts between public and private sectors are essential for advancing the biopharmaceutical industry.